Gauss, a Menlo Park, CA-based developer of computer vision applications for healthcare, raised an additional $10m in funding.
The additional funding, which brings total Series C financing round to $30m, was led by The 4100 Group, a subsidiary of Delta Dental of Michigan and Ohio, with additional participation from existing investors including SoftBank Ventures Asia, Northwell Health, Providence Health and Services, OSF Healthcare and Polaris Partners. The 4100 Group’s Managing Director of Private Market Investments, Scott Lancaster, MD, MBA, will join Gauss’s Board of Directors.
The company will use the funds to continue to advance its COVID-19 at-home rapid antigen test and computer-vision app. Gauss expects to announce the clinical trial results soon and the technology is already in use to power large-scale, at-home research studies on COVID-19.
Founded in 2011 and led by CEO Siddarth Satish, Gauss is the leader in computer vision in healthcare. Its flagship product, Triton, leverages computer vision to detect surgical and obstetric hemorrhage in real time and notifies clinicians who can enact timely intervention and treatment. Triton was granted De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014, as the first-ever computer vision software for surgical use, and several follow-on 510(k) clearances. Available on the iPhone, Triton has been widely adopted by health systems in the United States.
Last month, the company announced an exclusive partnership with Cellex, a biotechnology company specializing in point-of-care diagnostic testing, to launch a rapid, at-home and point-of-care COVID-19 antigen test. If authorized by the Food and Drug Administration (FDA) under Emergency Use Authorization (EUA), the test would be the first allowing people to test themselves for active COVID-19 infection and receive rapid results within their own home or similar user environments.